NewBridge to Offer Verinata's Verifi Test in Middle East, Africa | GenomeWeb

NEW YORK (GenomeWeb News) – NewBridge Pharmaceuticals today announced an agreement to offer Verinata Health's non-invasive prenatal tests in the Middle East and surrounding areas.

Under the exclusive agreement, NewBridge will offer Verinata's Verifi test in the Middle East, Africa, Turkey, and Caspian regions. Financial terms of the deal were not disclosed.

Based in Dubai, United Arab Emirates, NewBridge is a specialty therapeutics firm that commercializes pharmaceuticals, biologics, diagnostics, and medical devices in the Middle East and neighboring areas.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: researchers explore the transfer of host genetic material into viruses, and more.

It's too difficult to correct or retract a flawed scientific paper, researchers write in Nature.

A proposed bill would require NSF to only fund research that's in "the national interest."

Australia's Commonwealth Scientific and Industrial Research Organisation plans to eliminate up to 350 jobs.

Feb
25
Sponsored by
Omicia

This webinar will demonstrate how ACMG's recommended variant scoring and classification rules may be applied to standardize reporting on sequencing test results within and across institutions. 

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies. 

Mar
17
Sponsored by
Qiagen

This webinar will discuss Qiagen's approach to address two challenges facing NGS in the clinical research setting: lack of seamless workflow for routine clinical research use and truly relevant content to guide clinical research activities.